The Zacks Analyst Blog Highlights: Orion Marine Group, MasTec, Primoris Services, BioDelivery Sciences International and Endo

   The Zacks Analyst Blog Highlights: Orion Marine Group, MasTec, Primoris
    Services, BioDelivery Sciences International and Endo Health Solutions

PR Newswire

CHICAGO, Aug. 15, 2013

CHICAGO, Aug. 15, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Orion Marine Group,
Inc.(NYSE:ORN-Free Report), MasTec, Inc.(NYSE:MTZ-Free Report), Primoris
Services(Nasdaq:PRIM-Free Report), BioDelivery Sciences International,
Inc.(Nasdaq:BDSI-Free Report) and Endo Health Solutions
Inc.(Nasdaq:ENDP-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Orion Wins Wharf Contract

Orion Marine Group, Inc.(NYSE:ORN-Free Report), a leading heavy civil marine
contractor serving the infrastructure sector, recently won a $15 million
contract. The deal requires Orion to partially dismantle and reconstruct a

Additionally, according to the agreement, Orion will be responsible for
installing new crane rails for the Port of Tacoma in Tacoma, Wash. Orion
expects to begin the onsite construction during third-quarter 2013 and
complete the project in approximately 13 months.

The contract is the second of its kind procured by Orion in the last two
months. Recently, the company had received a contract award of $20 million in
the Gulf Coast region. The scope of the contract primarily involved
constructing and dredging a new ship dock for a private client in the region.

Orion is believed to have one of the strongest dredging equipments in the
industry. Some of the company's main customers include the U.S. Marine
Transportation System and the cruise industry. The company is one of the
leading providers of a broad range of marine construction and contracting

However, of late, Orion's share prices witnessed a downturn after it missed
its second-quarter earnings estimates. Shares of Orion were down about 5.4%
after the quarterly results and closed at $10.42 on Aug 13, after touching a
low of $9.90 on Aug 7. The second-quarter results were posted on Aug 1.
Earnings per share came in at a penny, which was below the Zacks Consensus
Estimate of 3 cents. However, it improved from a loss of 20 cents in the same
quarter last year.

Post the earnings miss, analysts have revised their estimates downwards for
both 2013 and 2014. The Zacks Consensus Estimate for 2013 is now 11cents, down
from 14 cents before the second-quarter earnings release. The 2014 consensus
is currently pegged at 29 cents, down from the previous estimate of 36 cents
over the last 30-day period.

With falling estimates, investors should remain cautious about this stock
which currently has a Zacks Rank #5 (Sell). Better-placed stocks within the
industry that are worth a look include MasTec, Inc.(NYSE:MTZ-Free Report)
andPrimoris Services(Nasdaq:PRIM-Free Report), which both carry a Zacks Rank
#2 (Buy).

BioDelivery Sciences Posts Loss Y/Y

BioDelivery Sciences International, Inc.(Nasdaq:BDSI-Free Report) reported
second-quarter 2013 loss of 35 cents per share wider than the Zacks Consensus
Estimate of a loss of 34 cents. The company reported earnings of 12 cents per
share in the year-ago period.

Quarter in Details

Quarterly revenues decreased sharply by 83% to $2.7 million. However, revenues
were marginally higher than the Zacks Consensus Estimate of $2 million.
Revenues were lower mainly because of contract revenues which stood at $1.9
million in the reported quarter, down 88%. The year-ago quarter included a $15
million milestone payment from Endo associated with the granting of a patent.

Research and development (R&D) expenses increased 91% to $12.8 million. Two
pivotal pain studies and an ongoing phase III safety study under BioDelivery
Sciences' collaboration agreement withEndo Health Solutions
Inc.(Nasdaq:ENDP-Free Report), led to the increase. The two pivotal chronic
pain studies for BEMA buprenorphine are slated to finish later this year or
early 2014.

The increase was also due to the NDA submission of its candidate, Bunavail in
Jul 2013. The company is looking to get Bunavail approved for the maintenance
treatment of opioid dependence.

Meanwhile, BioDelivery Sciences is looking to move clonidine topical gel, the
third product in its pain franchise, into a phase IIb study later this year
for the treatment of painful diabetic neuropathy.

General and Administrative (G&A) expenses increased 41% to $3.1 million,
mainly due to increased stock based compensation expense.

BioDelivery Sciences presently carries a Zacks Rank #3 (Hold).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on ORN - FREE

Get the full Report on MTZ - FREE

Get the full Report on PRIM - FREE

Get the full Report on BDSI - FREE

Get the full Report on ENDP - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.